Cleo Diagnostics (ASX:COV) Receivables Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:COV Cleo Diagnostics Ltd ASX:COV
32 GF Score
Price A$0.33
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Cleo Diagnostics's Revenue for the six months ended in Jun. 2026 was A$0.00 Mil. Cleo Diagnostics's average Accounts Receivable for the six months ended in Jun. 2026 was A$0.10 Mil.

Cleo Diagnostics  (ASX:COV) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Cleo Diagnostics Receivables Turnover Related Terms

Cleo Diagnostics Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Receivables Turnover Chart

Cleo Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Receivables Turnover
- - - - -

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Receivables Turnover Get a 7-Day Free Trial - - - - -

ASX:COV vs ABT, SYK, MDT: Receivables Turnover Comparison

For the Medical Devices subindustry, Cleo Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics Receivables Turnover vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Receivables Turnover falls into.


ASX:COV
32GF Score
Cleo Diagnostics Ltd ASX:COV
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Cleo Diagnostics's Receivables Turnover for the fiscal year that ended in Jun. 2026 is calculated as

Receivables Turnover (A: Jun. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (A: Jun. 2026 ) / ((Accounts Receivable (A: Jun. 2025 ) + Accounts Receivable (A: Jun. 2026 )) / count )
=0 / ((0.07057 + ) / 1 )
=0 / 0.07057
=N/A

Cleo Diagnostics's Receivables Turnover for the quarter that ended in Jun. 2026 is calculated as

Receivables Turnover (Q: Jun. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2026 ) / ((Accounts Receivable (Q: Dec. 2025 ) + Accounts Receivable (Q: Jun. 2026 )) / count )
=0 / ((0.098017 + ) / 1 )
=0 / 0.098017
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is an Australian medical diagnostics company developing blood-based in vitro diagnostic tests for the detection and monitoring of ovarian cancer. Its lead product candidate, the CXCL10 Triage Test, is designed to distinguish malignant ovarian cancer from benign gynecological conditions in women presenting with pelvic masses, addressing a diagnostic gap that currently requires surgery for confirmation. The company is also advancing tests for ovarian cancer recurrence and for screening applications. Cleo Diagnostics targets the clinical diagnostics market, selling to hospitals, gynecological oncology practices, and pathology laboratories, with an initial focus on Australia and the United States. Its revenue model is expected to center on sales of diagnostic test kits and related laboratory services, complemented by potential licensing and partnership arrangements with larger diagnostic companies. The company is listed on the Australian Securities Exchange.
32GF Score

Get the complete analysis for ASX:COV

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.33
Price